Hematologic Malignancy
High Grade B-Cell Lymphoma with MYC, BCL2, and BCL6 Rearrangements
CI-CAN-00009269Explore in graph →
Hematologic11 active trials
- NCIt
- C131913
- OncoTree
- HGBCLMYCBCL2
- UMLS CUI
- C4524190
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00009269Explore in graph →
Clinical trials
16 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (2)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04323956 | Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma | active not recruiting | Phase 1 | 50 | Mayo ClinicOTHER | 1 | Feb 2, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Feb 2, 2026source: clinicaltrials